Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Royalty Pharma PLC banner

Royalty Pharma PLC
NASDAQ:RPRX

Watchlist Manager
Royalty Pharma PLC Logo
Royalty Pharma PLC
NASDAQ:RPRX
Watchlist
Price: 44.38 USD 0.38% Market Closed
Market Cap: $25.6B
Write Note Create Alert Ask AI
Financials Section:
Income Statement Balance Sheet Cash Flow Statement
|
Revenue Breakdown

Income Statement

Revenue
+
3Y
+5%
5Y
+17%
10Y
-
Operating Income
+
3Y
+63%
5Y
-41%
10Y
-
Net Income
+
3Y
+51%
5Y
-56%
10Y
-

Earnings Waterfall
Royalty Pharma PLC

Income Statement
Royalty Pharma PLC

Rotate your device to view
Income Statement
Currency: USD
Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024 Sep-2024 Dec-2024 Mar-2025 Jun-2025 Sep-2025
Revenue
Interest Expense
269
255
220
183
157
141
144
157
166
176
185
188
188
188
188
187
187
184
187
207
226
247
266
279
Revenue
1 814
N/A
1 880
+4%
1 934
+3%
2 008
+4%
2 122
+6%
2 194
+3%
2 239
+2%
2 286
+2%
2 290
+0%
2 279
0%
2 260
-1%
2 247
-1%
2 237
0%
2 359
+5%
2 361
+0%
2 324
-2%
2 355
+1%
2 239
-5%
2 238
0%
2 266
+1%
2 264
0%
2 264
+0%
2 305
+2%
2 350
+2%
Operating Income
Operating Expenses
809
674
702
606
(462)
(762)
(470)
(700)
(859)
(857)
(1 206)
(1 304)
(1 314)
(1 793)
(1 924)
(1 928)
(862)
(1 299)
(1 277)
(722)
(971)
(363)
(465)
(817)
Selling, General & Administrative
(103)
(117)
(130)
(155)
(182)
(187)
(189)
(187)
(183)
(191)
(198)
(200)
(227)
(261)
(257)
(264)
(250)
(222)
(229)
(228)
(237)
(290)
(507)
(570)
Research & Development
(83)
(68)
(52)
(34)
(26)
(21)
(19)
(104)
(200)
(298)
(295)
(230)
(177)
(77)
(77)
(102)
(52)
(52)
(52)
(2)
(2)
(52)
(352)
(402)
Depreciation & Amortization
(24)
(23)
(23)
(23)
(23)
(23)
(23)
(23)
(23)
(23)
(17)
(12)
(6)
0
0
0
0
0
0
0
0
0
0
0
Other Operating Expenses
1 019
881
906
818
(231)
(531)
(240)
(386)
(453)
(345)
(695)
(862)
(904)
(1 454)
(1 590)
(1 562)
(561)
(1 025)
(997)
(492)
(732)
(22)
395
155
Operating Income
2 623
N/A
2 554
-3%
2 635
+3%
2 613
-1%
1 661
-36%
1 433
-14%
1 768
+23%
1 586
-10%
1 431
-10%
1 421
-1%
1 054
-26%
943
-11%
923
-2%
566
-39%
437
-23%
397
-9%
1 492
+276%
939
-37%
960
+2%
1 544
+61%
1 292
-16%
1 900
+47%
1 841
-3%
1 533
-17%
Pre-Tax Income
Interest Income Expense
(162)
(374)
(32)
198
139
315
185
(33)
(184)
(203)
(151)
(31)
(62)
61
47
(20)
230
270
87
188
40
(131)
(167)
(222)
Non-Reccuring Items
0
0
0
(25)
(96)
0
0
0
0
0
0
0
(616)
0
0
0
0
0
0
0
0
0
0
0
Gain/Loss on Disposition of Assets
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Other Income
0
(6)
(5)
(4)
(2)
4
3
1
(6)
(8)
(8)
(18)
(15)
(16)
(14)
(5)
(22)
(23)
(18)
(18)
(2)
(1)
(8)
(8)
Pre-Tax Income
2 461
N/A
2 174
-12%
2 598
+19%
2 782
+7%
1 702
-39%
1 752
+3%
1 957
+12%
1 554
-21%
1 241
-20%
1 210
-2%
895
-26%
894
0%
230
-74%
611
+166%
471
-23%
373
-21%
1 700
+356%
1 187
-30%
1 030
-13%
1 714
+66%
1 331
-22%
1 769
+33%
1 665
-6%
1 303
-22%
Net Income
Tax Provision
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Income from Continuing Operations
2 461
2 174
2 598
2 782
1 702
1 752
1 957
1 554
1 241
1 210
895
894
230
611
471
373
1 700
1 187
1 030
1 714
1 331
1 769
1 665
1 303
Income to Minority Interest
(113)
(122)
(255)
(558)
(727)
(779)
(985)
(771)
(622)
(608)
(429)
(387)
(187)
(279)
(216)
(188)
(565)
(388)
(357)
(569)
(472)
(676)
(644)
(538)
Net Income (Common)
2 349
N/A
1 981
-16%
1 863
-6%
1 745
-6%
495
-72%
564
+14%
972
+72%
783
-19%
620
-21%
602
-3%
466
-23%
507
+9%
43
-92%
332
+675%
255
-23%
184
-28%
1 135
+515%
799
-30%
673
-16%
1 145
+70%
859
-25%
1 093
+27%
1 021
-7%
765
-25%
EPS (Diluted)
3.94
N/A
3.33
-15%
5.26
+58%
4.71
-10%
1.32
-72%
0.92
-30%
1.6
+74%
1.28
-20%
1.49
+16%
0.99
-34%
0.76
-23%
0.83
+9%
0.1
-88%
0.54
+440%
0.42
-22%
0.3
-29%
1.88
+527%
1.33
-29%
1.12
-16%
1.93
+72%
1.44
-25%
1.88
+31%
1.81
-4%
1.36
-25%

See Also

Summary
RPRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
RPRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RPRX stock valuation using valuation multiples.
Wall Street Estimates
RPRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RPRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 317,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.